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Abstract
Objective—To assess the performance of rapid HIV antibody tests when used as part of a home-
based community-wide counselling and testing strategy in northern Malawi.
Design—A cross-sectional population survey of HIV infection, 2007-2008.
Methods—Adults aged 15 or over in a demographic surveillance area were counselled and then
offered an HIV test at their home by government certified counsellors. Two initial rapid tests
(Detemine™ and Uni-Gold™) were performed on all samples, and a third, tie-breaker test (SD
Bioline) used to resolve discordant results. All people who wanted to know were post-test
counselled and informed of their results, with referral to local clinical services if found to be HIV
positive. Laboratory quality control comprised re-testing all positive and every tenth negative
venous blood sample collected.
Results—A total of 10819 adults provided venous blood samples for HIV-testing, of whom 7.5%
(813) were HIV positive. The accuracy of the parallel testing strategy used was high, with 99.6%
sensitivity, 100.0% specificity, 99.9% positive predictive value and 99.9% negative predictive
values.
Conclusion—Face-to-face rapid testing by health personnel with minimum training, at the
clients’ home performs well when used on a wide scale in the community setting.
Keywords
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Introduction
Rapid HIV antibody tests are widely used for a range of public health and clinic purposes.
The rapid tests are relatively easy to perform with minimum equipment and training; and
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results can typically be obtained within 20 minutes, making the rapid tests well-suited for
use in settings where trained laboratory technicians and specialist equipment may be limited
[1,2]. In Africa, evaluation of the performance of rapid tests in the research setting,
including in mobile and community-based health clinics and information centres, have
shown high sensitivity and specificity [1,3,4]; however their performance in the home-based
community setting is unclear. Uncertainties have, moreover, been expressed over the
accuracy of rapid tests performed in mobile laboratories set up in local buildings or tents in
Rakai District, Uganda [5]. In that report an unacceptably high rate of false positive results
was found (43.7%, 129 of 295, total 1517 samples), attributed by the authors to the
classification of weak positive bands from Determine™ HIV-1/2/O (Abbott Laboratories,
Abbott Park, IL) and Uni-Gold™ Recombinant HIV-1/2 (Trinity Biotech, Bray, Ireland)
tests as a positive result, when in fact they should be negative.
In Malawi, rapid tests have been incorporated into the national scale up of HIV Testing and
Counselling (HTC) and the provision of anti-retroviral therapy (ART) through government
services, both of which are free at the point of delivery [6]. With an increasing emphasis on
universal testing and promotion of early initiation of antiretroviral therapy [7], a greater
amount of HIV testing will need to be performed at, or closer to the home to increase
numbers of tests and access for those least able to seek facility –based testing [8]. This
requires confidence in the testing procedure. Home based testing is being introduced in
several African countries [9,10,11,12] as a means to increasing uptake of testing [13]. Whilst
making testing accessible by this approach appears to be feasible and desired by individuals,
accuracy of this procedure will need to be carefully and regularly assessed, to ensure
accuracy is equal or better than laboratory based testing. We report our experience of home-
based community HIV rapid testing in Karonga District, northern Malawi.
Methods
Setting and Design
The Karonga Prevention Study (KPS) is a community-based research site, situated in
Chilumba, a small lakeshore settlement in Karonga district in rural northern Malawi. The
site includes a laboratory that functions to international standards. A population of
approximately 33,500 individuals in an area close to Chilumba has been under continuous
demographic surveillance since September 2004 [14]. HIV prevalence in adults in this area
in 2006 was estimated at 11.6% [15]. Here we report on an home-based cross-sectional
survey of HIV in adults, which took place in the same area between September 2007 and
October 2008, as part of a four year study to assess the impact of ART on HIV transmission
in the study population.
All homes in the study area were visited village-by-village; in each village, community
sensitization in relation to the study took place shortly before home visits. Any person in the
study population who was aged 15 years or over at the time of the household visit was
eligible for inclusion in the survey. The survey interviews and HTC were conducted by
counsellors who had been trained and certified by Ministry of Health staff to perform HIV
counselling, whole-blood rapid testing and specimen collection by finger-prick, using
standard training procedures [6]. At each home the study was introduced and explained to all
members, participants who, after pre-test counselling, consented to HIV-testing were asked
to provide a venous blood sample, with finger-pricks offered as an alternative if the
participant preferred. The whole blood was then tested immediately for HIV at the home, all
participants who wanted to know were post-test counselled and informed of their results,
with referral to local clinical services if found to be HIV positive.
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Community-based rapid testing
In Malawi, a whole-blood testing strategy for HIV-1 and HIV-2 is recommended and can be
performed by non-laboratory health personnel with minimum basic training, provided that
minimum standards for quality assurance are in place [6]. Until May 2008 a parallel testing
strategy was used. This strategy is based on performing two initial rapid tests simultaneously
on all samples and a third rapid test used only if the results are discordant; if any two rapid
test results are concordant, that result is taken as the final rapid test result and reported to the
client. After May 2008 a serial testing strategy was introduced after analysis and research
which determined that this approach was appropriate [6]. Under the serial testing strategy,
one initial rapid test is performed on all samples, a second rapid test is only performed if the
first result is positive or inconclusive, and a third performed only if the first two results are
discordant. Under both testing strategies the approved rapid tests combined Determine™
HIV-1/2 (Abbott Japan Co Ltd, Tokyo, Japan) with Uni-Gold™ HIV (Trinity Biotech PLC,
Bray, Ireland) as the first and second rapid tests respectively, using SD Bioline HIV 1/2 3.0
(Standard Diagnostics Inc, Kyonggi-do, Korea) as a third tie-breaker. All three rapid tests
used in Malawi are a one step, visual test for the detection of antibodies to HIV types 1 and
2 in human serum, plasma or whole blood; the test kits (including test device and reagent)
can be stored between 2-27°C; they have been reported to have sensitivities and specificities
of, respectively, 100% and 99.4% (Determine™), 100% and 100% (Uni-Gold™), and 100%
and 99.3% (SD Bioline) when evaluated under standard operational conditions [16,17].
The testing protocol followed by the HIV sero-survey followed the Malawi Ministry of
Health guidelines for whole-blood parallel rapid testing, throughout the entire survey round,
except that whole venous blood (taken by paramedical staff who had been certified by the
Malawi Medical Council to perform phlebotomy), was used to perform the rapid test rather
than finger-prick specimens, as this facilitated further laboratory-based HIV-related viral
testing, including quality control testing. Determine™, Uni-Gold™ and SD Bioline test kits
were stored in a cold room in the laboratory at 4-8° C until ready for use in the community
setting, then carried at ambient temperatures to the field; counsellors took with them to the
field sufficient supplies to meet at least one day’s needs and restocked when necessary.
At the home, counsellors were required to use a flat, dry surface for the rapid tests according
to manufacturers’ guidelines, and to protect the rapid tests from environmental
contamination by keeping the test devices inside a closed box while waiting for the results.
The blood sample was collected in a S-Monovette® EDTA tube (Sarstedt, Nümbrecht,
Germany), and from this placed immediately on the test device using a disposable plastic
pipette. A mechanical timer was used, and the counsellors were instructed to read and
interpret rapid test results 20 minutes after having added reagents, consistent with the
manufacturers’ instructions. For all rapid test devices, counsellors were instructed that any
band in the positive region was to be considered reactive to HIV irrespective of the strength
of the band; if the rapid test was uninterpretable by virtue of a failed control band it was to
be considered inconclusive, according to the manufacturers’ instructions. Tests were
performed for one participant at a time, or together for a couple, in which latter situation the
test devices were labelled with a marker pen to distinguish between the male and female
partners and hence reduce the risk of muddling of test results. Test results were transcribed
onto a dedicated rapid-test form, with the outcome of each interview identified by a unique
study number, rather than by the participant’s name. Specimens were transported at ambient
temperature to the laboratory at KPS at the end of the working day, refrigerated at 2-8°C
overnight and then registered the next day for storage and confirmatory testing.
MOLESWORTH et al. Page 3
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2011 December 30.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Laboratory-based quality control
Laboratory-based quality control at KPS was conducted by systematically re-testing plasma
from all samples that were positive, inconclusive or for which the initial two rapid tests were
discordant using the parallel testing strategy, and from every tenth negative sample
collected. The first 500 negative community samples collected in 2007 were re-tested, in
view of findings from Rakai, Uganda reported early the same year. The quality control “gold
standard” HIV tests comprised two parallel HIV antibody tests: the Edgware modification
[18] of the Serodia® HIV-1/2 (Fujirebio Inc, Tokyo, Japan) particle agglutination test and
the Vironostika® HIV Uni-Form II plus O (bioMérieux bv, Boxtel, The Netherlands) EIA
test, and was performed blind to the community rapid-test results. Initial discordance in the
laboratory between the Edgware and Vironostika® tests was resolved by repeating the
Edgware and Vironostika® tests for that sample. Discordance between the laboratory quality
control outcome and the community rapid-test results was addressed by laboratory-based
repeat rapid-testing testing of first that sample, and then all samples collected on the same
day for any clinical or research reason, in order to assess the likelihood of results being
wrongly transcribed or of specimen mix-ups caused by mislabelling the specimens or data
forms in the field or laboratory i.e. ensuring no positive samples from that day which had
been reported negative and could therefore account for a false positive result on laboratory
QC. All results were reviewed, if necessary arranging a follow-up visit to the participant
and, in the case of samples that could not be resolved locally, sending the sample to a
reference laboratory before assigning the final HIV summary result.
External quality assurance at KPS was based on retesting a panel of six specimens, provided
thrice annually by the United Kingdom National External Quality Assurance Service for
Microbiology (UK NEQAS). Ministry of Health staff and national reference-laboratory
personnel were also invited to observe testing practices, and retest a sample of specimens.
Re-testing of finger-prick samples was not undertaken.
Statistical Analyses
We assessed the performance of the rapid tests by comparing the results of community-
based parallel testing with those from laboratory-based quality control. Confidence intervals
were calculated using exact methods. All analyses were conducted in STATA 9.2 software
(StataCorp, College Station, Texas, USA).
Results
Between September 2007 and October 2008, a total of 11172 of 16894 eligible adults agreed
to HIV testing. Of these, 10819 provided a venous blood sample for HIV testing and are
included in subsequent analyses; data for 331 participants who preferred to give finger-prick
samples and 22 for whom the original rapid-test results or specimen were missing, are
excluded from analyses and not considered further here.
The rapid test results using the parallel strategy are shown in Figure 1. Overall, 7.5% (813 of
10819) of the clients tested were HIV positive; the final outcome of all rapid tests was
positive or negative; with any inconclusive initial test results resolved through applying the
testing algorithm. In over 99.4% of samples (10752 of 10819) there was concordance
between the Determine™ and Uni-Gold™ test result. Overall, a total of 9954 samples tested
negative by Determine™, of which eight were positive with the Uni-Gold™ test result; only
one remained positive after the SD Bioline tie-break was used. None of the 9954 would have
been further tested after the initial Determine™ test had a serial testing strategy been used,
so one HIV positive case would have been missed.
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A total of 2911 blood samples collected were subjected to internal laboratory-based quality
control; these comprised all 813 positive samples and 2098 negative samples identified by
the community-based parallel testing strategy, and included 67 samples for which the initial
two rapid tests were discordant. The performance of community-based rapid HIV testing is
presented by rapid test strategy in Table 1, using the parallel Edgware and Vironostika®
laboratory quality control tests as the gold standard. The parallel rapid testing strategy
actually used gave a high sensitivity and specificity, and high positive and negative
predictive values. In only four samples there was discordancy between the overall laboratory
and the community HIV test result; for one of these samples the specimen was brought back
to the office for testing as the participant did not wish to know their results; re-testing of all
specimens collected on the same day did not reveal any specimen mix-up arising from
mislabelling but it is possible that the interviewer tested the wrong specimen at the office or
incorrectly transcribed the rapid test results. For the remaining three samples discordancy is
more likely to have arisen as a result of sample peculiarities; there having been discordancy
between the initial Determine™ and Uni-Gold™ rapid tests conducted at the household,
between the initial Edgware and Vironostika® quality control tests conducted in the
laboratory, and between the laboratory rapid re-tests. In terms of rapid test performance a
similar outcome would have been reached had the same samples that were selected for
laboratory quality-control been tested using the national serial testing strategy.
We estimated the cost of rapid test kits in the first survey round at just over $26,019.20,
based on a per-test median international transaction price of $0.80 for Determine™ and SD
Bioline, and $1.60 for Uni-Gold™ [19]; the equivalent cost under a serial testing strategy,
had this been applied would have been $10,086.40. Alternatively in our setting the cost of
test kits per HIV-infection diagnosed would be $32.0 under the parallel system and $12.4
under the serial test system.
Discussion
Our results provide evidence that rapid-testing conducted in a “point-of-service”
community-setting by non-laboratory health personnel with adequate training, combined
with a system that ensures quality control, accurately determines the presence or absence of
antibodies to HIV. At the level of the individual tests discordance rate between Determine™
and Uni-Gold™ was low; when used together in a parallel or serial strategy, with SD
Bioline as a tie-breaker test, we have found that in this setting, the positive predictive value
of the rapid tests (whether in a parallel or serial strategy) when compared to the parallel
Edgware and Vironostika® laboratory testing strategy as gold standard is high. We are
confident that a result in the community can be reported to the client, and that there is no
need to discriminate between light and dark bands, which is difficult to do objectively and
therefore has practical limitations.
In our study population there has been no indication of the problems with rapid test
performance with Determine™ and Uni-Gold™ that had been observed elsewhere. The
reasons for this are unclear; the performance of rapid tests for HIV antibody might be
affected by early or acute HIV infection, during the period preceding the emergence of
antibody, but it is unlikely this could have played a major role when incidence is
substantially less than 1% per year. Variation in the test accuracy between different HIV
subtypes (such as the dominant HIV-1 subtype C in Malawi, compared with subtypes A and
D, and AD recombinants found in Uganda) and in the potential for cross-reactions with a
different spectrum of endemic infections may in part be responsible [5]. However a more
likely explanation for general variation in rapid test performance in different African
settings, may relate to transport and storage of test kits and specimens and conditions under
which the rapid tests were performed. In Malawi, rapid test kits were used for home-based
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whole blood HIV testing, contributing to optimal conditions for the collection, labelling and
testing of specimens and confirmation of results; the use of whole blood from a venous
specimen rather than a direct finger-prick guaranteed the required volume of whole blood.
There is little in the literature comparing finger prick with whole blood for HIV rapid testing
in situations of service delivery, however it would seem prudent to ensure adequate attention
is paid to training staff in the optimal performance of finger pricks with correct lancets to
ensure adequate volumes of blood. The performance of CD4 T-cell counts has been
demonstrated to be reproducible when done in this way [20]. We did not incorporate a direct
comparison of finger prick versus venous blood as this was not the primary purpose of this
study, but subsequent work will need to consider this. In contrast, situations involving the
transportation of the clients’ specimens away from the point of specimen collection can
increase the opportunity for mislabelling of specimens, and where the testing process relies
on the prior preparation of laboratory serum samples under field conditions, this may also
affect the technical performance of the rapid tests used. Overall, given appropriate attention
to the detail of storing and transporting of test kits, which are reasonably robust and
temperature stable, and to the collection and testing of an appropriate volume of blood, we
feel it likely that our results can be reproduced in service settings.
Our consideration of the performance of home-based community-testing under a serial
testing strategy indicates that one participant out of the 10819 specimens tested would have
been given a different result had the parallel testing strategy been used. While we found that
in our population a parallel testing strategy provides HIV test results with high sensitivity,
specificity and predictive values; a serial testing strategy affords very nearly the same level
of accuracy at approximately 40% of the test kit cost. Our study has demonstrated that rapid
HIV tests perform well when used on a wide scale in the home-based community setting.
The recorded prevalence in this study of 7.5% was lower than the estimated 11.6%, but this
was primarily explained by refusals to test in those who already new their status to be
positive from previous rounds of testing, thus lowering the measured prevalence form
previous surveys [15]. The high sensitivity of Determine™ and high specificity of Uni-
Gold™ make them very well suited as screening and confirmatory tests respectively; when
combined in series, with a system that ensures the appropriate storage of test devices and
reagents, adherence to protocol when conducting rapid tests, and regular supervision of
operator procedures to ensure that sample mix-ups and the potential reporting of wrong
results do not occur, face-to-face rapid testing by government trained staff at the clients’
home can be of high accuracy. Laboratory based quality-control of field results should also
be an essential component of home based testing, as it should of any system that is relying
on remotely performed rapid HIV tests. This helps to ensure the quality of the tests by direct
confirmation of accuracy and also by the indirect effects of ensuring operators are subjected
to supervision of their testing accuracy and are motivated by this. The intensity of laboratory
quality control in routine practice is not immediately obvious from our results. Our approach
of all positives and a random selection of similar numbers of field test negatives is probably
unnecessarily intense. The actual numbers of quality control tests may be less important in a
public health based testing initiative than ensuring random sampling and feedback is done
on a regular basis and on random samples to ensure that counsellors can be confident that
this process is on-going and helpful.
As an initiative to increase access to and uptake of “point-of-service” HIV testing and
consequent referral for appropriate care, we can be reassured that home-based counselling
and rapid HIV testing is acceptable to both counsellors and their clients in the community
setting.
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Figure 1.
Outcome of rapid HIV testing by Determine™ test result
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